ACM
AKRO

ADAR1 Capital Management’s Akero Therapeutics AKRO Stock Holding History

ADAR1 Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,143
Closed -$292K – 271
2025
Q3 		$292K Sell
6,143
-27,000
-81% -$1.31M 0.03% 163
2025
Q2 		$1.77M Sell
33,143
-38,000
-53% -$1.73M 0.27% 59
2025
Q1 		$2.88M Buy
71,143
+55,836
+365% +$2.37M 0.53% 49
2024
Q4 		$426K Sell
15,307
-7,700
-33% -$233K 0.09% 118
2024
Q3 		$660K Sell
23,007
-2,500
-10% -$65.2K 0.11% 100
2024
Q2 		$598K Buy
25,507
+23,700
+1,312% +$507K 0.11% 90
2024
Q1 		$45.6K Sell
1,807
-14,193
-89% -$341K 0.01% 185
2023
Q4 		$374K Buy
+16,000
New +$316K 0.13% 66

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADAR1 Capital Management's AKRO Position: Q4 2025 in Review

ADAR1 Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,143 shares — an estimated $292K sold.

ADAR1 Capital Management first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $2.88M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • ADAR1 Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 6,143 Akero Therapeutics shares in Q4 2025, an estimated $292K.
  • ADAR1 Capital Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
  • ADAR1 Capital Management's Akero Therapeutics position peaked at $2.88M in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on ADAR1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.